|
|
|
|
| LEADER |
03011nmm a2200265 u 4500 |
| 001 |
EB000365382 |
| 003 |
EBX01000000000000000218434 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
130626 ||| eng |
| 020 |
|
|
|a 9781592598663
|
| 100 |
1 |
|
|a Adams, Val R.
|e [editor]
|
| 245 |
0 |
0 |
|a Camptothecins in Cancer Therapy
|h Elektronische Ressource
|c edited by Val R. Adams
|
| 250 |
|
|
|a 1st ed. 2005
|
| 260 |
|
|
|a Totowa, NJ
|b Humana Press
|c 2005, 2005
|
| 300 |
|
|
|a XIII, 460 p
|b online resource
|
| 505 |
0 |
|
|a Biochemistry, Pharmacology, and Chemistry -- Mechanism of Action of Topoisomerase 1 Poisons -- Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage -- Inhibitors of Topoisomerase I Function -- Cytotoxic Mechanisms of Topoisomerase 1 Inhibitors -- Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage -- Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs -- Mechanisms of Resistance to Camptothecins -- Recent Advances in Camptothecin Drug Design and Delivery Strategies -- Clinical Perspectives -- Clinical Experience With 9-Aminocamptothecin -- Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin) -- Irinotecan -- Clinical Experience With Topotecan -- The Clinical Development of Lurtotecan -- Preclinical and Clinical Development of Exatecan (DX-951f) -- Camptothecins in the Treatment of Primary Brain Tumors -- Camptothecins in the Treatment of Lung Cancer -- Use of Camptothecins in the Treatment of Leukemia and Related Disorders
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Oncology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Cancer Drug Discovery and Development
|
| 856 |
4 |
0 |
|u https://doi.org/10.1385/1592598668?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 520 |
|
|
|a Clinical interest in the camptothecins continues to expand even though this class of topoisomerase I inhibitors has been studied for almost 50 years, and two early generation members of the family have gained FDA approval. In Camptothecins in Cancer Therapy, leading clinicians and researchers critically review our current understanding of camptothecins, their shortcomings, and the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance. Authoritative and up-to-date, Camptothecins in Cancer Therapy provides a comprehensive summary of camptothecin research, as well as a much-needed guide to all the latest information on their optimal therapeutic applications
|